A phase 3 trial demonstrates multiple benefits of adding the androgen-receptor inhibitor darolutamide to standard therapy.
Matthew Smith, MD, PhD
Matthew Smith, MD, PhD
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Departments, Centers, & Programs:
Mass General Cancer Center: Center for Genitourinary Cancers
55 Fruit St.
Boston, MA 02114
- MD, Duke University School of Medicine
- Residency, Brigham and Women's Hospital
- Fellowship, Dana Farber Cancer Institute
American Board Certifications
- Medical Oncology, American Board of Internal Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr. Smith leads a clinical research program in prostate cancer focused on cancer survivorship, treatment and prevention of bone metastases, and novel therapeutics. With a multidisciplinary research team, he identified previously unrecognized adverse effects of androgen deprivation therapy including osteoporosis, sarcopenia, obesity, lipid alterations, insulin resistance, and greater risks for fractures, diabetes, and cardiovascular disease. These novel observations have provided fundamental insights in the management of prostate cancer and informed the design of global clinical trials to prevent treatment-related morbidity in prostate cancer survivors. His research has contributed to the approval of new drugs to prevent skeletal morbidity in men with prostate cancer. He leads international studies to prevent and treat bone metastases. He leads an active clinical research program in novel therapy for prostate cancer. His research program is supported by principal investigator peer-reviewed research funding from federal, investigator-initiated industry, and foundation grants including an NIH K24 mid-career investigator award and a Prostate Cancer Foundation Transformational grant. He has authored more than 70 original research reports and more than 80 reviews and book chapters on prostate cancer.
Related News and Articles
- Dec | 1 | 2018
New research by Matthew Smith, MD, PhD, director of Genitourinary Malignancies Program, and colleagues has identified a therapy, apalutamide, that can delay the spread of cancer in nmCRPC patients